Compare SAP & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAP | MRK |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.4B | 260.2B |
| IPO Year | 1998 | N/A |
| Metric | SAP | MRK |
|---|---|---|
| Price | $244.62 | $100.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $340.75 | $109.13 |
| AVG Volume (30 Days) | 1.5M | ★ 15.8M |
| Earning Date | 01-27-2026 | 10-30-2025 |
| Dividend Yield | 0.78% | ★ 3.39% |
| EPS Growth | ★ 159.50 | 58.08 |
| EPS | 7.07 | ★ 7.56 |
| Revenue | $42,818,256,487.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $9.53 | $1.97 |
| Revenue Next Year | $10.96 | $4.96 |
| P/E Ratio | $34.62 | ★ $13.27 |
| Revenue Growth | ★ 9.70 | 1.68 |
| 52 Week Low | $233.51 | $73.31 |
| 52 Week High | $313.28 | $105.84 |
| Indicator | SAP | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 59.78 |
| Support Level | $242.10 | $96.06 |
| Resistance Level | $247.88 | $99.85 |
| Average True Range (ATR) | 3.33 | 2.46 |
| MACD | 1.51 | -0.70 |
| Stochastic Oscillator | 65.04 | 43.03 |
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).